TLR7 and cancer: Given that certain TLR ligands, in particular the TLR7/8 ligand resiquimod (R848), and the TLR9 ligand CpG, can elicit a strong immune response, these ligands may be used as adjuvants during treatment of virus-infected or cancer patients with high numbers of Tregs [22], [23].